Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 540222 | NSE: LAURUSLABS | Pharmaceuticals & Drugs | Small Cap
1. Is Laurus Labs Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Laurus Labs Ltd is a good quality company.
2. Is Laurus Labs Ltd undervalued or overvalued?
The key valuation ratios of Laurus Labs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Laurus Labs Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Laurus Labs Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||0%||15.4%||10%||12.4%||12%||9.1%||6.5%||11.8%||29.6%||19.5%||-|
|Value Creation Index ⓘ||NA||0.1||-0.3||-0.1||-0.1||-0.3||-0.5||-0.2||1.2||0.7||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||NA||14.4%||34%||7.2%||8%||11.5%||23.6%||70%||2.5%||-|
|Adj EPS ⓘ||0||3.2||1.6||4.3||3.3||2.9||1.9||4.8||18.1||15.3||14.7|
|YoY Gr. Rt. %||-||NA||-48.3%||161%||-23.1%||-11.6%||-34%||150%||277.3%||-15.6%||-|
|BVPS (₹) ⓘ||0||9.5||21||25||25.1||27.9||29.2||33||48.3||62.2||75|
|Adj Net Profit ⓘ||0||97.6||50.9||135||174||154||102||256||972||821||790|
|Cash Flow from Ops. ⓘ||0||121||-64.7||182||332||342||298||347||733||911||-|
|Debt/CF from Ops. ⓘ||0||4.5||-12.7||5.7||2.5||2.9||3.5||3||2||1.9||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||NA||36%||99.7%||-15.6%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||0||27.2||9.4||17.1||15.9||11||6.7||15.4||44.5||27.6||21.4|
|Op. Profit Mgn % ⓘ||0||18||15.1||20.5||21.4||20.1||16.1||20||32.2||28.8||26.4|
|Net Profit Mgn % ⓘ||0||8.4||3.8||7.6||9.2||7.5||4.5||9.1||20.2||16.7||13.1|
|Debt to Equity ⓘ||0||1.5||1.1||1.2||0.6||0.7||0.7||0.6||0.6||0.5||0.2|
|Working Cap Days ⓘ||0||0||210||197||212||222||227||220||191||243||226|
|Cash Conv. Cycle ⓘ||0||0||106||112||131||136||130||119||81||121||67|
Sales growth is growing at healthy rate in last 3 years 29.14%
Net Profit is growing at healthy rate in last 3 years 99.65%
Debt to equity has declined versus last 3 years average to 0.52
Sales growth is good in last 4 quarters at 24.60%
Return on Equity has declined versus last 3 years average to 21.40%
|TTM EPS (₹)||14.1||14.7|
|TTM Sales (₹ Cr.)||5,773||6,041|
|BVPS (₹.) ⓘ||75.3||75|
|Reserves (₹ Cr.) ⓘ||3,949||3,930|
|From the Market|
|52 Week Low / High (₹)||279.65 / 605.50|
|All Time Low / High (₹)||59.60 / 723.55|
|Market Cap (₹ Cr.)||18,688|
|Equity (₹ Cr.)||107.7|
|Face Value (₹)||2|
|Industry PE ⓘ||38.1|
The company was originally incorporated as Laurus Labs Private Limited on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company under the Companies Act, 1956. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited and a fresh certificate of incorporation consequent upon change of name on conversion to a public limited company was issued by the Registrar of Companies, Andhra Pradesh and Telangana, located at Hyderabad (RoC) on February 12, 2007. Subsequently the name of the company was changed to Aptuit Laurus Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on July 19, 2007. Thereafter, the cmpany was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited and a fresh certificate of incorporation consequent upon change of name on conversion to a private limited company was issued by the RoC on July 24, 2007. Subsequently the name of the company was changed to Laurus Labs Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on February 21, 2012. The company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited and a fresh certificate of incorporation consequent upon change of name on conversion to a public limited company was issued by the RoC on August 16, 2016.
Laurus Labs Limited is a public company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on two recognised stock exchanges in India. Laurus Labs develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. It works with all the top generic pharmaceutical companies in the world. The company sells its APIs in many countries. Its major focus areas include anti-retroviral, Hepatitis C and Oncology drugs. Continuous innovation is the lifeblood of its business. Therefore, it undertake dedicated R&D in areas that have significant growth potential. The company has commercialised various products since inception across three distinct business units: Generics API, Generics FDF and Synthesis.
Business area the company
Laurus Labs offers broad and integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry.